PMID: 22339125Feb 22, 2012Paper

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

Current HIV Research
Dénes BánhegyiFrank Tomaka

Abstract

Long-term potent activity of antiretrovirals is essential for HIV-1-infected, treatment-experienced patients. TITAN (TMC114/r In Treatment-experienced pAtients Naive to lopinavir) compared Week-96 efficacy and safety of darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r). Treatment-experienced, LPV-naive, HIV-1-infected patients were randomised to DRV/r 600/100 mg bid or LPV/r 400/100 mg bid plus optimised background regimen (≥ 2 NRTIs/NNRTIs). 595 patients were enrolled (mean baseline HIV-1 RNA: 4.30 log10 copies/mL; median CD4 count: 232 cells/mm3). At Week 96, more DRV/r than LPV/r patients achieved HIV-1 RNA < 400 copies/mL (66.8% versus 58.9% [intent-to-treat (ITT)/time-to-loss of virological response (TLOVR)], estimated difference 8.7%, 95% confidence interval [CI]: 0.7-16.7), demonstrating the primary endpoint of non-inferiority of DRV/r (p < 0.001); the difference in response was statistically significant (p = 0.034). For the secondary efficacy parameter (HIV-1 RNA < 50 copies/mL) at Week 96, response to DRV/r was 60.4% versus 55.2% for LPV/r (ITT-TLOVR), estimated difference 5.8%, 95% CI: -2.3-13.9. Virological failure (VF; HIV-1 RNA > 400 copies/mL) with DRV/r (13.8%) was nearly half that with LPV/r (25.6%)...Continue Reading

Citations

Feb 20, 2013·Clinical Pharmacokinetics·Frederik E StuurmanJan H M Schellens
Jun 16, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rodger D MacArthur, Herbert L DuPont
Aug 12, 2014·Current Opinion in Pharmacology·Xudong WuHuiping Zhou
May 12, 2015·Expert Review of Anti-infective Therapy·Thomas N KakudaGoedele de Smedt
Nov 28, 2015·Expert Opinion on Pharmacotherapy·Amedeo CapettiGiuliano Rizzardini
Sep 1, 2014·Clinical Pharmacology in Drug Development·Thomas N KakudaRichard M W Hoetelmans
Nov 9, 2012·HIV Clinical Trials·Edgar Turner OvertonFrank Tomaka
Dec 20, 2014·The Journal of Antimicrobial Chemotherapy·José R SantosJosé Moltó
Sep 30, 2015·The American Journal of Tropical Medicine and Hygiene·Siwalee RattanapunyaKesara Na-Bangchang
Oct 11, 2017·Expert Review of Clinical Pharmacology·Robert Pope, Angela Kashuba
May 17, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sidonie Lambert-NiclotLaurence Morand-Joubert
Jun 12, 2020·Therapeutic Advances in Infectious Disease·Caroline FosterSarah Fidler
Mar 7, 2020·The Journal of Antimicrobial Chemotherapy·Jordi NavarroEsteban Ribera
Oct 3, 2018·The Journal of Antimicrobial Chemotherapy·Emilie R ElliotMarta Boffito
Apr 13, 2021·Journal of Zhejiang University. Science. B·Yong-Zheng GuoBiao Zhu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.